<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[eben tessari Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/eben+tessari.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to eben tessari]]></description>
	<s:counts start="0" returned="20" found="25" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Biogen to Collaborate on Cancer Treatment]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F127818-biogen-to-collaborate-on-cancer-treatment%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: AVEO and Biogen BIIB announced a strategic collaboration for the development and commercialization of AVEO&#8217;s novel discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and other diseases.  TERMS by Eben Tessari]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Mar 2009 08:04:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Merck to Buy Schering-Plough in $41.1 Billion Cash and Stock Deal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F124932-merck-to-buy-schering-plough-in-41-1-billion-cash-and-stock-deal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Not to be outdone by Pfizer PFE / Wyeth WYE, Merck MRK and Schering-Plough SGP announced that their Boards of Directors have unanimously approved a merger. Schering has a strong pipeline and was my best of breed to be acquired in the medium sized pharmaceutical space. I...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 09 Mar 2009 08:49:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Vertex to Buy Hepatitis C Drug Developer ViroChem for $375 Million]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F124128-vertex-to-buy-hepatitis-c-drug-developer-virochem-for-375-million%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Vertex VRTX, which is developing the hepatitis C virus (HCV) protease inhibitor telaprevir, will add two polymerase inhibitors to its HCV drug development portfolio through an agreement to acquire privately-held ViroChem Pharma in a stock and cash transaction. The move expands Vertex&#8217;s global presence in HCV and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 04 Mar 2009 10:36:54 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/vertex+pharmaceuticals+inc..html"><![CDATA[Vertex Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VRTX</category>
		<category domain="tickers">VRTX</category>
	</item>
	<item>
		<title><![CDATA[Astellas Announces Offer to Buy CV Therapeutics]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F123565-astellas-announces-offer-to-buy-cv-therapeutics%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Astellas (ALPMF.PK) announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics CVTX at a price of US$16.00 per share. The offer and withdrawal rights are scheduled to expire at 12:01 a.m., New...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 02 Mar 2009 07:54:53 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/cv+therapeutics+inc..html"><![CDATA[CV Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVTX</category>
		<category domain="tickers">CVTX</category>
	</item>
	<item>
		<title><![CDATA[Lilly Taps NeuroSearch for Preclinical Discovery Deal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F121241-lilly-taps-neurosearch-for-preclinical-discovery-deal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Just a week after NeuroSearch failed a phase II pain trial (ABT-894), they&#8217;ve inked a collaboration which will focus on new CNS therapeutics based upon defined ion channel targets. NeuroSearch is eligible to receive equity payments and research funding of up to USD 30 million over the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 18 Feb 2009 08:47:32 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Idenix and GSK Partner on HIV Treatment Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F119021-idenix-and-gsk-partner-on-hiv-treatment-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Idenix IDIX and GlaxoSmithKline GSK announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.Terms Upfront: $34M ($17M in cash; $17M equity stake @ 6.87/share or ~17% premium to 30 day trailing ave) Milestones: $416M Royalties: Double digit tiered Development: GSK assumes all...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 06 Feb 2009 05:34:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/idenix+pharmaceuticals+inc..html"><![CDATA[Idenix Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IDIX</category>
		<category domain="tickers">GSK,IDIX</category>
	</item>
	<item>
		<title><![CDATA[Astellas Proposes to Acquire CV Therapeutics for $1Billion]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F116824-astellas-proposes-to-acquire-cv-therapeutics-for-1billion%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Astellas (ALPMF.PK) announced that it has submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash. The proposal represents a 41% premium to the closing share price of CV Therapeutics on...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 27 Jan 2009 01:04:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
	</item>
	<item>
		<title><![CDATA[5 Reasons Pfizer Shouldn't Buy Wyeth]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F116358-5-reasons-pfizer-shouldn-t-buy-wyeth%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Reasons to buy Wyeth WYE Misery loves company.  Reasons not to buy Wyeth by Eben Tessari]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 25 Jan 2009 10:08:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Jumps Into Hepatitis C Race]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F114610-bristol-myers-jumps-into-hepatitis-c-race%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Bristol-Myers Squibb BMY has decided to jump into the hotter by the second race for hepatitis C therapies. BMS and ZymoGenetics have entered a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 13 Jan 2009 11:57:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Cubist and Alnylam, An Odd Partnership]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F114245-cubist-and-alnylam-an-odd-partnership%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:  Cubist CBST and Alnylam ALNY have formed a strategic collaboration to develop and commercialize Alnylam&#8217;s ALN-RSV program. The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 11 Jan 2009 09:57:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cubist+pharmaceuticals+inc..html"><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CBST</category>
		<category domain="tickers">ALNY,CBST</category>
	</item>
	<item>
		<title><![CDATA[BioMarin Rolls the Dice on a New Lupus Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F113883-biomarin-rolls-the-dice-on-a-new-lupus-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: BioMarin Pharmaceutical BMRN and La Jolla Pharmaceutical Company announced that they have entered into an agreement to develop and commercialize Riquent®, La Jolla&#8217;s investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Following a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 08 Jan 2009 08:02:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/biomarin+pharmaceutical+inc..html"><![CDATA[BioMarin Pharmaceutical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMRN</category>
		<category domain="tickers">BMRN</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Allies With Dynavax to Target Autoimmune Diseases]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F111246-glaxosmithkline-allies-with-dynavax-to-target-autoimmune-diseases%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: GlaxoSmithKline GSK and Dynavax DVAX announced a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. Dynavax&#8217;s lead inhibitor drug candidate, DV1079, is a bifunctional inhibitor of TLR7 and TLR9, and is expected to enter...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 17 Dec 2008 07:19:57 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/dynavax+technologies+corp..html"><![CDATA[Dynavax Technologies Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DVAX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">DVAX,GSK</category>
	</item>
	<item>
		<title><![CDATA[Ascent Enters $200M Pact With Novartis]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F109947-ascent-enters-200m-pact-with-novartis%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:  Ascent Therapeutics announced that it has entered into a licensing option agreement through the Novartis Option Fund. Ascent will discover and develop Pepducin drug candidates against a specific GPCR target. The agreement includes an upfront fee and potential milestones totaling over $200 million as well as...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 09 Dec 2008 12:07:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Can MicroRNA Reverse Heart Disease?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F108559-can-microrna-reverse-heart-disease%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Regulus Therapeutics, a joint venture between Alnylam ALNY and Isis ISIS formed to discover, develop, and commercialize microRNA-based therapeutics, announced the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure.  Apparently, this is the first...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 01 Dec 2008 07:57:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ALNY,ISIS</category>
	</item>
	<item>
		<title><![CDATA[JNJ / Omrix: Potential Synergies]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F107593-jnj-omrix-potential-synergies%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Johnson & Johnson JNJ and Omrix Biopharmaceuticals OMRI, a biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 24 Nov 2008 07:34:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/omrix+biopharmaceuticals+inc..html"><![CDATA[Omrix Biopharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">OMRI</category>
		<category domain="tickers">JNJ,OMRI</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers' Collaboration with Exelixis Is Looking Lucrative]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F107588-bristol-myers-collaboration-with-exelixis-is-looking-lucrative%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Exelixis announced that Bristol-Myers Squibb BMY has exercised its option to develop and commercialize Exelixis&#8217; investigational new drug (IND) candidate XL413, a selective inhibitor of Cdc7.  XL413 is a small molecule inhibitor of the serine-threonine kinase Cdc7. The function of Cdc7 is required for DNA replication...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 24 Nov 2008 07:22:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/exelixis+inc..html"><![CDATA[Exelixis Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EXEL</category>
		<category domain="tickers">BMY,EXEL</category>
	</item>
	<item>
		<title><![CDATA[BBM Looks for Bargain in YM Biosciences Acquisition Proposal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F106132-bbm-looks-for-bargain-in-ym-biosciences-acquisition-proposal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Talk about a tough market, according to a recent report, half of all biotech&#8217;s with a market cap under $200M are trading for less than cash on hand. YM Biosciences YMI  is no exception and BBM is trying to snag a bargain.  Under BBM&#8217;s proposal, BBM...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sat, 15 Nov 2008 02:18:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/common+stock.html"><![CDATA[Common Stock]]></category>
		<category domain="http://resources.bnet.com/topic/bargain.html"><![CDATA[Bargain]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/bbm.html"><![CDATA[BBM]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
	</item>
	<item>
		<title><![CDATA[ArQule Joins Forces with Daiichi Sankyo to Fight Cancer]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F105369-arqule-joins-forces-with-daiichi-sankyo-to-fight-cancer%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:  ArQule and Daiichi Sankyo announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. One agreement covers the license of ARQ 197 and the other is an R&D agreement.  ARQ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Nov 2008 08:13:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[Agreement]]></category>
		<category domain="http://resources.bnet.com/topic/cancer.html"><![CDATA[Cancer]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/arq+197.html"><![CDATA[ARQ 197]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/arqule+inc..html"><![CDATA[ArQule Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARQL</category>
		<category domain="tickers">ARQL</category>
	</item>
	<item>
		<title><![CDATA[Will TorreyPines Sale of Its Alzheimer Genetics Research Save the Company?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F105365-will-torreypines-sale-of-its-alzheimer-genetics-research-save-the-company%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: TorreyPines Therapeutics, Inc. TPTX Tuesday announced that it has agreed to sell its Alzheimer&#8217;s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Nov 2008 07:58:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/torreypines+stock.html"><![CDATA[TorreyPines Stock]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/torreypines+therapeutics+inc..html"><![CDATA[TorreyPines Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">TPTX</category>
		<category domain="tickers">TPTX</category>
	</item>
	<item>
		<title><![CDATA[Onyx's $320M Bet on BTG's Anticancer Compound]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F105088-onyx-s-320m-bet-on-btg-s-anticancer-compound%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:  BTG has granted the worldwide commercialization and development rights of BGC 945, a novel anticancer compound, to Onyx ONXX in exchange for a potential $320M.  BGC 945 is a novel compound that inhibits thymidylate synthase (TS), an enzyme involved in cell growth and division. However,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 10 Nov 2008 09:53:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[Compound]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+software.html"><![CDATA[Onyx Software]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[Cell]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/bgc+945.html"><![CDATA[BGC 945]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
</channel>
</rss>
